Strata, Clovis deal
Strata and Clovis partnered to accelerate patient enrollment in Clovis' TRITON program of Rubraca rucaparib. The program includes Phase II and III trials of Rubraca to treat metastatic castration-resistant prostate cancer. Strata will receive an undisclosed upfront fee and is eligible for per-patient fees and milestones. Strata will use its Strata Trial, an observational study that uses next-generation sequencing, to identify breast cancer early onset (BRCA) and ataxia telangiectasia mutated (ATM)-mutated advanced prostate cancer patients for the Phase II TRITON2 and Phase III TRITON3 trials. The companies declined to disclose additional financial terms...